TY - JOUR
T1 - Acute myeloid leukaemia with myelodysplastic features in children
T2 - A report of Japanese Paediatric Leukaemia/Lymphoma Study Group
AU - Kinoshita, Akitoshi
AU - Miyachi, Hayato
AU - Matsushita, Hiromichi
AU - Yabe, Miharu
AU - Taki, Tomohiko
AU - Watanabe, Tomoyuki
AU - Saito, Akiko M.
AU - Tomizawa, Daisuke
AU - Taga, Takashi
AU - Takahashi, Hiroyuki
AU - Matsuo, Hidemasa
AU - Kodama, Kumi
AU - Ohki, Kentaro
AU - Hayashi, Yasuhide
AU - Tawa, Akio
AU - Horibe, Keizo
AU - Adachi, Souichi
N1 - Publisher Copyright:
© 2014 John Wiley & Sons Ltd.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Summary: The clinical characteristics and prognostic relevance of acute myeloid leukaemia (AML) with myelodysplastic features remains to be clarified in children. We prospectively examined 443 newly diagnosed patients in a multicentre clinical trial for paediatric de novo AML, and found 'AML with myelodysplasia-related changes' (AML-MRC) according to the 2008 World Health Organization classification in 93 (21·0%), in whom 59 were diagnosed from myelodysplasia-related cytogenetics alone, 28 from multilineage dysplasia alone and six from a combination of both. Compared with 111 patients with 'AML, not otherwise specified' (AML-NOS), patients with 'AML-MRC' presented at a younger age, with a lower white blood cell count, higher incidence of 20-30% bone marrow blasts, unfavourable cytogenetics and a lower frequency of Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), NPM1 and CEBPA mutations. Complete remission rate and 3-year probability of event-free survival were significantly worse in 'AML-MRC' patients (67·7 vs. 85·6%, P < 0·01, 37·1% vs. 53·8%, P = 0·02, respectively), but 3-year overall survival and relapse-free survival were comparable with 'AML-NOS' patients. By multivariate analysis, FLT3-ITD was solely associated with worse overall survival. These results support the distinctive features of the category 'AML-MRC' even in children.
AB - Summary: The clinical characteristics and prognostic relevance of acute myeloid leukaemia (AML) with myelodysplastic features remains to be clarified in children. We prospectively examined 443 newly diagnosed patients in a multicentre clinical trial for paediatric de novo AML, and found 'AML with myelodysplasia-related changes' (AML-MRC) according to the 2008 World Health Organization classification in 93 (21·0%), in whom 59 were diagnosed from myelodysplasia-related cytogenetics alone, 28 from multilineage dysplasia alone and six from a combination of both. Compared with 111 patients with 'AML, not otherwise specified' (AML-NOS), patients with 'AML-MRC' presented at a younger age, with a lower white blood cell count, higher incidence of 20-30% bone marrow blasts, unfavourable cytogenetics and a lower frequency of Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), NPM1 and CEBPA mutations. Complete remission rate and 3-year probability of event-free survival were significantly worse in 'AML-MRC' patients (67·7 vs. 85·6%, P < 0·01, 37·1% vs. 53·8%, P = 0·02, respectively), but 3-year overall survival and relapse-free survival were comparable with 'AML-NOS' patients. By multivariate analysis, FLT3-ITD was solely associated with worse overall survival. These results support the distinctive features of the category 'AML-MRC' even in children.
KW - Multilineage dysplasia
KW - Myelodysplasia
KW - Paediatric acute myeloid leukaemia
KW - WHO classification
UR - http://www.scopus.com/inward/record.url?scp=84909971208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84909971208&partnerID=8YFLogxK
U2 - 10.1111/bjh.12993
DO - 10.1111/bjh.12993
M3 - Article
C2 - 25039450
AN - SCOPUS:84909971208
SN - 0007-1048
VL - 167
SP - 80
EP - 86
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -